TG Therapeutics Inc (NASDAQ: TGTX) kicked off on Tuesday, up 1.85% from the previous trading day, before settling in for the closing price of $35.75. Over the past 52 weeks, TGTX has traded in a range of $15.16-$46.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 364.59% over the last five years. While this was happening, its average annual earnings per share was recorded 493.33%. With a float of $142.95 million, this company’s outstanding shares have now reached $158.17 million.
The firm has a total of 338 workers. Let’s measure their productivity. In terms of profitability, gross margin is 87.43%, operating margin of 15.48%, and the pretax margin is 10.8%.
TG Therapeutics Inc (TGTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of TG Therapeutics Inc is 9.96%, while institutional ownership is 62.71%. The most recent insider transaction that took place on Jan 03 ’25, was worth 343,443. In this transaction CFO of this company sold 11,337 shares at a rate of $30.29, taking the stock ownership to the 670,632 shares. Before that another transaction happened on Jan 06 ’25, when Company’s CFO sold 10,021 for $28.53, making the entire transaction worth $285,939. This insider now owns 660,611 shares in total.
TG Therapeutics Inc (TGTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 493.33% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Take a look at TG Therapeutics Inc’s (TGTX) current performance indicators. Last quarter, stock had a quick ratio of 3.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.24, a number that is poised to hit 0.20 in the next quarter and is forecasted to reach 1.78 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
Analysing the last 5-days average volume posted by the [TG Therapeutics Inc, TGTX], we can find that recorded value of 1.51 million was lower than the volume posted last year of 2.7 million. As of the previous 9 days, the stock’s Stochastic %D was 77.09%. Additionally, its Average True Range was 1.71.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 47.66%, which indicates a significant decrease from 84.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.87% in the past 14 days, which was lower than the 58.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.66, while its 200-day Moving Average is $31.24. Now, the first resistance to watch is $37.21. This is followed by the second major resistance level at $38.00. The third major resistance level sits at $38.96. If the price goes on to break the first support level at $35.46, it is likely to go to the next support level at $34.50. Should the price break the second support level, the third support level stands at $33.71.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
The company with the Market Capitalisation of 5.78 billion has total of 158,755K Shares Outstanding. Its annual sales at the moment are 329,000 K in contrast with the sum of 23,380 K annual income. Company’s last quarter sales were recorded 120,860 K and last quarter income was 5,060 K.
